A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia
This study has been completed.
Sponsor:
Eli Lilly and Company
Information provided by:
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT00089869
First received: August 16, 2004
Last updated: July 18, 2006
Last verified: July 2006
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Study of a medication for the treatment of Schizophrenia in patients who are already taking Abilify, Risperdal, Seroquel, Zyprexa
| Condition | Intervention | Phase |
|---|---|---|
|
Schizophrenia |
Drug: olanzapine Drug: atomoxetine Drug: placebo |
Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Primary Purpose: Treatment |
Resource links provided by NLM:
Further study details as provided by Eli Lilly and Company:
Eligibility| Ages Eligible for Study: | 18 Years to 55 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Must have a clinical diagnosis of Schizophrenia
- Must be at least 18 years of age and not older than 55 years of age
- Must have been stable on a dose of Abilify, Risperdal, Seroquel, or Zyprexa for the past 8 weeks
- Women of childbearing potential must be using a medically accepted means of contraception
- Must be able to swallow capsules
Exclusion Criteria:
- Has serious health problems other than Schizophrenia
- Takes an antidepressant for depression
- Takes insulin for diabetes
- Have a history of alcohol or drug dependence (except for nicotine and caffeine) within the past 6 months
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00089869
Locations
| United States, California | |
| "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician." | |
| Cerritos, California, United States | |
| "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician. | |
| Chula Vista, California, United States | |
| For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician. | |
| Garden Grove, California, United States | |
| "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician." | |
| San Diego, California, United States | |
| United States, Connecticut | |
| "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician." | |
| New Haven, Connecticut, United States | |
| For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician. | |
| New Haven, Connecticut, United States | |
| United States, Georgia | |
| "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician." | |
| Atlanta, Georgia, United States | |
| United States, Illinois | |
| "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician." | |
| Chicago, Illinois, United States | |
| United States, Indiana | |
| "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician." | |
| Indianapolis, Indiana, United States | |
| United States, Iowa | |
| "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician." | |
| Iowa City, Iowa, United States | |
| United States, Minnesota | |
| "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician." | |
| Minneapolis, Minnesota, United States | |
| United States, New Hampshire | |
| "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician." | |
| Lebanon, New Hampshire, United States | |
| United States, New York | |
| "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician." | |
| New York, New York, United States | |
| United States, North Carolina | |
| "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician." | |
| Butner, North Carolina, United States | |
| "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician." | |
| Chapel Hill, North Carolina, United States | |
| United States, Oklahoma | |
| "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician." | |
| Okalahoma City, Oklahoma, United States | |
| United States, Texas | |
| "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician." | |
| Austin, Texas, United States | |
| "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician." | |
| Irvin, Texas, United States | |
| For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician. | |
| Irving, Texas, United States | |
| "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician." | |
| San Antonio, Texas, United States | |
Sponsors and Collaborators
Eli Lilly and Company
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00089869 History of Changes |
| Other Study ID Numbers: | 8269, H6U-MC-HGLM |
| Study First Received: | August 16, 2004 |
| Last Updated: | July 18, 2006 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Schizophrenia Schizophrenia and Disorders with Psychotic Features Mental Disorders Atomoxetine Olanzapine Adrenergic Uptake Inhibitors Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Neurotransmitter Uptake Inhibitors Physiological Effects of Drugs |
Antipsychotic Agents Tranquilizing Agents Central Nervous System Depressants Central Nervous System Agents Therapeutic Uses Psychotropic Drugs Serotonin Uptake Inhibitors Serotonin Agents Antiemetics Autonomic Agents Peripheral Nervous System Agents Gastrointestinal Agents |
ClinicalTrials.gov processed this record on May 19, 2013